Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02022202 · ClinicalTrials.gov registry record
Breast Cancer Genome Guided Therapy Study (BEAUTY)
A clinical trial of Invasive Breast Cancer, sponsored by Mayo Clinic.
- Completed
- Registry status
- 140
- Enrollment target
- 2
- Study locations
NCT02022202: Completed study of Invasive Breast Cancer, sponsored by Mayo Clinic.
NCT02022202 is a study of Invasive Breast Cancer that has completed, run by Mayo Clinic. The registered enrollment target is 140 participants, above the 125-participant average among 19 other Invasive Breast Cancer trials with a reported enrollment target (12% higher). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02022202, a study of Invasive Breast Cancer, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- 140 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this research study is to better understand the reasons why or why not breast cancers are destroyed by standard chemotherapy. This information will be used to develop new and better cancer therapies.
Primary Outcome
To obtain DNA from the germline and breast tumor for the identification of novel somatic changes within gene and gene pathways that are potentially "druggable" in men or women with breast cancer undergoing a standard neoadjuvant paclitaxel (with or without trastuzumab), followed by a standard anthracycline containing regimen (e.g. doxorubicin and cyclophosphamide) for breast cancer. We will report the median frequency and range of mutations observed for 30 mutated genes of interest.
Conditions Studied
Study Locations (2)
Arizona
- Mayo Clinic campus in Arizona - Scottsdale
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2012-03-03 |
| Est. Completion | 2020-12-31 |
What the finished NCT02022202 record still lists
NCT02022202 is an observational study that tracks outcomes without assigning an intervention. The registered 140 participants enrollment target is mid-sized for trials with a published cap, above the 125-participant average among 19 other Invasive Breast Cancer trials with a reported enrollment target (12% higher).
The record links to 1 condition, with Invasive Breast Cancer appearing as the primary indexed condition, and to 0 interventions.
NCT02022202 reports a single indexed study location in Arizona, Minnesota.
Frequently Asked Questions
What is clinical trial NCT02022202 about?
NCT02022202 is a clinical study titled "Breast Cancer Genome Guided Therapy Study (BEAUTY)". The purpose of this research study is to better understand the reasons why or why not breast cancers are destroyed by standard chemotherapy. This information will be used to develop new and better cancer therapies.
What is the current status of trial NCT02022202?
This trial is currently completed. The enrollment target is 140 participants. The study started on 2012-03-03. Estimated completion is 2020-12-31.
What conditions does trial NCT02022202 study?
This clinical trial studies the following conditions: Invasive Breast Cancer.
Who is sponsoring clinical trial NCT02022202?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02022202 being conducted?
This trial has 2 study locations across Arizona, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Invasive Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02022202's enrollment target sits among peer trials
140 5th of 19 higher than 15 of 19 other Invasive Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Invasive Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
CONFIRM: Magnetic Resonance Guided Radiation Therapy
RECRUITING · NA
-
TRUDI: TDXD+Durva in HER2+/Low IBC
RECRUITING · Phase 2
-
A Study of an Alternative Treatment Approach (Preoperative Radiotherapy, Then Mastectomy, Then Immediate Reconstruction Surgery) in People With T4 Breast Cancer
RECRUITING · Phase 1
-
Impact of Vitamin D Supplementation on the Rate of Pathologic Complete Response in Vitamin D Deficient Patients
RECRUITING · Phase 2
-
Tart Cherry Juice as a Dietary Supplement for the Prevention of Paclitaxel-Induced Neuropathy
RECRUITING · Phase 2
-
(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01419561 · 140 participants · Phase 2
Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS)
- NCT01624805 · 140 participants · Phase 2
Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome
- NCT02369770 · 140 participants · NA
Sensory-Motor Rehabilitation Post Stroke
- NCT02455193 · 140 participants · NA
Neuronal Effects of Exercise in Schizophrenia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI